Rare Dermatological Conditions Update - Hidradenitis Suppurative and Alopecia Areata
This activity will provide pharmacists, residents, and technicians education on Hidradenitis Suppurative and Alopecia Areata. A discussion of the common features, outcomes, and medication used in each disease state will be utilized in order to bridge the current gap in knowledge. Pharmacists will be familiarized with the current treatment guidelines with an emphasis on the newly approved agents. A thorough discussion of the pathophysiology will be provided on each disease state in order to understand the mechanisms of agents that are currently in trial.
This activity is intended for pharmacists and pharmacy technicians.
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Describe the pathophysiology of Hidradenitis Suppurativa and Alopecia Areata
- Review treatment guidelines for each disease state
- Evaluate new therapeutic options
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Recognize common features of HS and Alopecia Areata
- Discuss outcomes associated with each disease
- Identify brand and generic names of the treatment options
Mason Snell, PharmD
PGY1 Community Pharmacy Resident
Ochsner Specialty Pharmacy
Natalie Tucker, PharmD, BCCCP
Ochsner Health Care
Alicia Verret, PharmD, CSP
Ochsner Specialty Pharmacy
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of content validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-22-099-L01-P
Universal Activity Number: JA0006103-9999-22-099-L01-T
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE – Attendance